# US 2026/0028381 A1 · Systems and methods for promoting trans-splicing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028381 A1
- Document ID: US20260028381A1
- Status: Published application
- Kind: A1
- Application number: 18/994,856
- Filed: 2023-05-19
- Published: 2026-01-29
- Earliest claimed: 2022-07-19
- Assignees: Tacit Therapeutics, Inc.
- Applicants: Tacit Therapeutics, Inc.
- Inventors: David Allen NELLES
- Web page: https://patentgrep.com/patent/US20260028381A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/86: Viral vectors
- C07K 2319/85: containing an RNA binding domain
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions systems and methods for promoting trans-splicing. In some examples, the system may comprise a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence. The system may further comprise a tethering fusion protein. The tethering fusion protein may promote an association of the exonic sequence and a target RNA or portion thereof.

## Claims

### Claim 1

A system for trans-splicing, comprising:
a. a nucleic acid molecule encoding:
i. an exonic sequence; and
ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
iii. one or more binding domains configured to interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences; and
b. said RNA binding protein, which is configured to insert said exonic sequence into said target RNA molecule.

### Claim 2 (depends on 1)

The system for trans-splicing of claim 1, wherein said intronic domain comprises said one or more binding domains.

### Claim 3 (depends on 1, 2)

The system for trans-splicing of claim 1 or 2, wherein the RNA binding protein is a tethering protein.

### Claim 4 (depends on 3)

The system for trans-splicing of claim 3, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 5 (depends on 4)

The system for trans-splicing of claim 4, wherein said non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 6 (depends on 4)

The system for trans-splicing of claim 4, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 7 (depends on 4)

The system for trans-splicing of claim 4, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 8 (depends on 3)

The system for trans-splicing of claim 3, wherein said tethering protein further comprises a domain configured to associate with an enzyme configured to insert said exonic sequence into said target mRNA molecule.

### Claim 9 (depends on 8)

The system for trans-splicing of claim 8, wherein said tethering protein further comprises an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule.

### Claim 10 (depends on 3)

The system for trans-splicing of claim 3, wherein said tethering protein is isolated or derived from human protein sequences.

### Claim 11

The system for trans-splicing of any one of the preceding claims, further comprising an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 12

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 13

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 14 (depends on 13)

The system for trans-splicing of claim 13, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 15

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 16

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 17

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 18 (depends on 17)

The system for trans-splicing of claim 17, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 19

The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 20

The system for trans-splicing of any one of the preceding claims, wherein said system for trans-splicing lacks a CRISPR-associated protein.

### Claim 21

A vector comprising the system for trans-splicing of any one of the preceding claims.

### Claim 22 (depends on 21)

The vector of claim 21, wherein said vector is selected from the group consisting of: adeno-associated virus, retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex, and dendrimer.

### Claim 23 (depends on 21)

A cell comprising the vector of claim 21.

### Claim 24

A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising a nucleic acid molecule according to any one of the preceding claims.

### Claim 25

A system for trans-splicing, comprising:
a. a nucleic acid molecule encoding:
i. an exonic sequence; and
ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
b. a protein configured to insert said exonic sequence into said target RNA molecule,
wherein said system for trans-splicing lacks a CRISPR-associated protein.

### Claim 26 (depends on 25)

The system for trans-splicing of claim 25, wherein said nucleic acid molecule encodes one or more binding sites for said protein.

### Claim 27 (depends on 26)

The system for trans-splicing of claim 26, wherein said protein is a tethering protein.

### Claim 28 (depends on 27)

The system for trans-splicing of claim 27, wherein said tethering protein is a fusion tethering protein.

### Claim 29 (depends on 27)

The system for trans-splicing of claim 27, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal protein.

### Claim 30 (depends on 29)

The system for trans-splicing of claim 29, wherein said tethering protein further comprises a domain that binds non-specifically to double-stranded RNA that stabilizes the RNA-RNA hybridization between said specific sequence encoded by said nucleic acid molecule and said target RNA.

### Claim 31 (depends on 27)

The system for trans-splicing of claim 27, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 32 (depends on 31)

The system for trans-splicing of claim 31, wherein said non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 33 (depends on 31)

The system for trans-splicing of claim 31, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 34 (depends on 31)

The system for trans-splicing of claim 31, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 35 (depends on 27)

The system for trans-splicing of claim 27, wherein said tethering protein is isolated or derived from human protein sequences.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system for trans-splicing of any one of claims 25-35, Further comprising an engineered small nuclear RNA derived or isolated from a Ut snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 37 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The system for trans-splicing of any one of claims 25-36, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 38 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The system for trans-splicing of any one of claims 25-37, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 39 (depends on 38)

The system for trans-splicing of claim 38, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 40 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The system for trans-splicing of any one of claims 25-39, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 41 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The system for trans-splicing of any one of claims 25-40, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The system for trans-splicing of any one of claims 25-41, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 43 (depends on 42)

The system for trans-splicing of claim 42, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 44 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The system for trans-splicing of any one of claims 25-43, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 45 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A vector comprising the system for trans-splicing of any one of claims 25-44.

### Claim 46 (depends on 45)

The vector of claim 45, wherein said vector is selected from the group consisting of: adeno-associated virus, retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex, and dendrimer.

### Claim 47 (depends on 45)

A cell comprising the vector of claim 45.

### Claim 48 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising a nucleic acid molecule according to any one of claims 25-47.

### Claim 49 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method for correcting a genetic defect in a subject comprising administering to said subject a nucleic acid molecule according to any one of claims 25-48.

### Claim 50

A nucleic acid molecule encoding:
a. an exonic sequence;
b. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
c. one or more binding domains that interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences, and wherein said RNA-binding protein is configured to interact with a transcriptional or spliceosomal enzyme coupled to said target RNA.

### Claim 51 (depends on 50)

The nucleic acid molecule of claim 50, wherein said system for trans-splicing lacks a CRISPR-associated protein.

### Claim 52 (depends on 50)

The nucleic acid molecule of claim 50, wherein said RNA-binding protein is a tethering protein.

### Claim 53 (depends on 51)

The nucleic acid molecule of claim 51, wherein said tethering protein is a tethering fusion protein.

### Claim 54 (depends on 52)

The nucleic acid molecule of claim 52, wherein said tethering protein further comprises an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule.

### Claim 55 (depends on 52)

The nucleic acid molecule of claim 52, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a transport domain that associates with a transcriptional or spliceosomal enzyme coupled to said target RNA.

### Claim 56 (depends on 55)

The nucleic acid molecule of claim 55, wherein the transport domain comprises sequences isolated or derived from a gene involved in transcription, mediator complex, and/or the spliceosome.

### Claim 57 (depends on 55)

The nucleic acid molecule of claim 55, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 58 (depends on 55)

The nucleic acid molecule of claim 55, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 59 (depends on 55)

The nucleic acid molecule of claim 55, wherein said tethering protein further comprises a domain that binds non-specifically to double-stranded RNA that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 60 (depends on 51)

The nucleic acid molecule of claim 51, wherein said tethering protein further comprises an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule.

### Claim 61 (depends on 51)

The nucleic acid molecule of claim 51, wherein said tethering protein is isolated or derived from human protein sequences.

### Claim 62 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The nucleic acid molecule of any one of claims 50-61, further comprising an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 63 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The nucleic acid molecule of any one of claims 50-62, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 64 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The nucleic acid molecule of any one of claims 50-63, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 65 (depends on 64)

The nucleic acid molecule of claim 64, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 66 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The nucleic acid molecule of any one of claims 50-65, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 67 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The nucleic acid molecule of any one of claims 50-66, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 68 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The nucleic acid molecule of any one of claims 50-67, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 69 (depends on 68)

The nucleic acid molecule of claim 68, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 70 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The nucleic acid molecule of any one of claims 50-69, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 71 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A vector comprising the system for trans-splicing of any one of claims 50-70.

### Claim 72 (depends on 71)

The vector of claim 71, wherein said vector is selected from the group consisting of: adeno-associated virus, retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex, and dendrimer.

### Claim 73 (depends on 71)

A cell comprising the vector of claim 71.

### Claim 74 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising the nucleic acid molecule according to any one of claims 50-73.

### Claim 75 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A method for correcting a genetic defect in a subject comprising administering to said subject the nucleic acid molecule according to any one of claims 50-74.

### Claim 76

A system for trans-splicing, comprising:
a. a nucleic acid molecule encoding:
i. an exonic sequence;
ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
iii. one or more binding domains that interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences; and
b. a tethering protein that promotes the association of said exonic sequence and said target RNA molecule, and wherein said tethering protein is configured to bind to said one or more binding domains.

### Claim 77 (depends on 76)

The system for trans-splicing of claim 76, wherein said tethering protein is a fusion protein.

### Claim 78 (depends on 77)

The system for trans-splicing of claim 77, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal protein.

### Claim 79 (depends on 77)

The system for trans-splicing of claim 77, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 80 (depends on 79)

The system for trans-splicing of claim 79, wherein said non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STA2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 81 (depends on 79)

The system for trans-splicing of claim 79, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 82 (depends on 79)

The system for trans-splicing of claim 79, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 83 (depends on 78, 79)

The system for trans-splicing of claim 78 or 79, wherein the tethering protein further comprises a domain that binds non-specifically to double-stranded RNA that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 84 (depends on 83)

The system for trans-splicing of claim 83, wherein said domain that binds non-specifically to double-stranded RNA comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 85 (depends on 77)

The system for trans-splicing of claim 77, wherein said tethering protein further comprises an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule.

### Claim 86 (depends on 77)

The system for trans-splicing of claim 77, wherein said tethering protein comprises: (a) an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal complex.

### Claim 87 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The system for trans-splicing of any one of claims 76-86, further comprising an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 88 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The system for trans-splicing of any one of claims 76-86, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 89 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The system for trans-splicing of any one of claims 76-88, wherein said nucleic acid further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 90 (depends on 89)

The system for trans-splicing of claim 89, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 91 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The system for trans-splicing of any one of claims 76-90, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 92 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The system for trans-splicing of any one of claims 76-91, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 93 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The system for trans-splicing of any one of claims 76-86, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 94 (depends on 93)

The system for trans-splicing of claim 93, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 95 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The system for trans-splicing of any one of claims 76-94, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 96 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

A vector comprising the system for trans-splicing of any one of claims 76-95.

### Claim 97 (depends on 96)

The vector of claim 96, wherein said vector is selected from the group consisting of: adeno-associated virus, retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex, and dendrimer.

### Claim 98 (depends on 96, 97)

A cell comprising the vector of claim 96 or 97.

### Claim 99 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising a nucleic acid molecule according to any one of claims 76-95.

### Claim 100 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

A method for correcting a genetic defect in a subject comprising administering to said subject a nucleic acid molecule according to any one of claims 76-95.

### Claim 101

A method of associating an exonic sequence with a target RNA, the method comprising:
a. providing a nucleic acid encoding:
i. an exonic sequence;
ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
iii. one or more binding domains that interact with a tethering protein; and
b. binding a tethering protein to said one or more binding domains and to said target RNA molecule to associate said exonic sequence with, said target RNA molecule.

### Claim 102 (depends on 101)

The method of claim 101, wherein said method is performed in the absence of a CRISPR-associated enzyme.

### Claim 103 (depends on 101)

The method of claim 101, wherein said tethering protein is a fusion protein.

### Claim 104 (depends on 102)

The method of claim 102, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal protein.

### Claim 105 (depends on 102)

The method of claim 102, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 106 (depends on 105)

The method of claim 105, wherein said non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 107 (depends on 105)

The method of claim 105, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 108 (depends on 105)

The method of claim 105, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 109 (depends on 102)

The method of claim 102, further comprising providing a enzyme configured to insert said exonic sequence into said target RNA molecule.

### Claim 110 (depends on 102)

The method of claim 102, wherein said tethering protein further comprises a doming configured to associate with said enzyme configured to insert said exonic sequence into said target RNA molecule.

### Claim 111 (depends on 102)

The method of claim 102, wherein said tethering protein further comprises an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule.

### Claim 112 (depends on 102)

The method of claim 102, wherein said tethering protein comprises: (a) an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal complex.

### Claim 113 (depends on 102)

The method of claim 102, wherein said tethering protein is isolated or derived from human protein sequences.

### Claim 114 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The method of any one of claims 101-113, further comprising providing an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 115 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 101-114, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 116 (depends on 115)

The method of claim 115, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 117 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The method of any one of claims 101-116, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 118 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The method of any one of claims 101-117, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 119 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 101-118, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 120 (depends on 119)

The method of claim 119, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 121 (depends on 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The method of any one of claims 101-120, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 122

A method of associating an exonic sequence with a target RNA, the method comprising:
a. providing a nucleic acid molecule encoding:
i. a exonic sequence; and
ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule; and
b. binding a tethering protein to said target RNA molecule and said exonic sequence to associate said exonic sequence with said target RNA molecule, wherein said trans-splicing molecule does not associate with a CRISPR enzyme.

### Claim 123 (depends on 122)

The method of claim 122, wherein said tethering protein is a fusion tethering protein.

### Claim 124 (depends on 122, 123)

The method of claim 122 or 123, wherein said tethering protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal protein.

### Claim 125 (depends on 122, 123, 124)

The method of any one of claims 122-124, wherein said tethering protein comprises: (a) an RNA-binding domain, that binds to a specific sequence encoded by said nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization between said specific sequence and said target RNA.

### Claim 126 (depends on 125)

The method of claim 125, wherein said non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 127 (depends on 125)

The method of claim 125, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 128 (depends on 125)

The method of claim 125, wherein said RNA-binding domain that binds to said specific sequence encoded by said nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 129 (depends on 122, 123, 124, 125, 126, 127, 128)

The method of any one of claims 122-128, further comprising providing a enzyme configured to insert said exonic sequence into said target RNA molecule.

### Claim 130 (depends on 122, 123, 124, 125, 126, 127, 128, 129)

The method of any one of claims 122-129, wherein said tethering protein further comprises a domain configured to associate with said enzyme configured to insert said exonic sequence into said target RNA molecule.

### Claim 131 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130)

The method of any one of claims 122-130, wherein said tethering protein comprises: (a) an RNA-binding domain configured to bind a specific sequence encoded by said nucleic acid molecule; and (b) a domain configured to associate with a transcriptional or spliceosomal complex.

### Claim 132 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The method of any one of claims 122-131, wherein said tethering protein is isolated or derived from human protein sequences.

### Claim 133 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The method of any one of claims 122-132, further comprising providing an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.

### Claim 134 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 122-133, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 135 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134)

The method of any one of claims 122-134, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.

### Claim 136 (depends on 135)

The method of claim 135, wherein said sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 137 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The method of any one of claims 122-136, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 138 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137)

The method of any one of claims 122-137, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 139 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138)

The method of any one of claims 122-138, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 140 (depends on 139)

The method of claim 139, wherein said gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 141 (depends on 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)

The method of any one of claims 122-140, wherein said nucleic acid molecule further encodes a heterologous promoter.

### Claim 142

A system for trans-splicing comprising a nucleic acid encoding an exonic sequence and a tethering fusion protein, wherein the tethering fusion protein promotes the association of the exonic sequence and a target RNA.

### Claim 143 (depends on 142)

The system for trans-splicing of claim 142, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization among the specific sequence encoded by the nucleic acid molecule and the target RNA.

### Claim 144 (depends on 143)

The system for trans-splicing of claim 143, wherein the non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH1.

### Claim 145 (depends on 143)

The system for trans-splicing of claim 143, wherein the RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 146 (depends on 143)

The system for trans-splicing of claim 143, wherein the RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 147 (depends on 142)

The system for trans-splicing of claim 142, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds a specific sequence encoded by said nucleic acid molecule; and (b) a domain that associates with the spliceosome.

### Claim 148 (depends on 142)

The system for trans-splicing of claim 142, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds a specific sequence encoded by said nucleic acid molecule; and (b) a domain that associates with a transcriptional or spliceosomal complex.

### Claim 149 (depends on 142, 143, 144, 145, 146, 147, 148)

The system for trans-splicing of any one of claims 142-148, wherein the tethering fusion protein is isolated or derived from human protein sequences.

### Claim 150 (depends on 142, 143, 144, 145, 146, 147, 148, 149)

The system for trans-splicing of any one of claims 142-149, further comprising an engineered small nuclear RNA derived or isolated from the U1 snRNA gene that promotes trans-splicing among the target RNA and exonic sequence.

### Claim 151 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150)

The system for trans-splicing of any one of claims 142-150, wherein the nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 152 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151)

The system for trans-splicing of any one of claims 142-151, wherein the exonic sequence further comprises a sequence promotes accumulation of the exonic sequence in the cellular nucleus.

### Claim 153 (depends on 152)

The system for trans-splicing of claim 152, wherein the sequence that promotes accumulation of the exonic sequence in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 154 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The system for trans-splicing of any one of claims 142-153, wherein the nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 155 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

The system for trans-splicing of any one of claims 142-154, wherein the nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 156 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The system for trans-splicing of any one of claims 142-155, wherein the nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 157 (depends on 156)

The system for trans-splicing of claim 156, wherein the gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 158 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

The system for trans-splicing of any one of claims 142-157, wherein the nucleic acid molecule comprises RNA, DNA, a DNA RNA hybrid, a nucleic acid analog, a chemically-modified nucleic acid, or a chimera composed of two or more nucleic acids or nucleic acid analogs.

### Claim 159 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158)

The system for trans-splicing of any one of claims 142-158, wherein the nucleic acid molecule further comprises a heterologous promoter.

### Claim 160 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

A vector comprising the system for trans-splicing of any one of claims 142-160.

### Claim 161 (depends on 160)

The vector of claim 160, wherein the vector is selected from the group consisting of: adeno-associated virus, retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex, and dendrimer.

### Claim 162 (depends on 160, 161)

A cell comprising the vector of claim 160 or 161.

### Claim 163 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising a nucleic acid molecule according to any one of claims 142-160.

### Claim 164 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

A method for correcting a genetic defect in a subject comprising administering to said subject a nucleic acid molecule according to any one of claims 142-160.

### Claim 165

A method of targeting an exonic sequence to a target RNA, the method comprising:
a. providing a nucleic acid encoding said exonic sequence;
b. providing said target RNA; and
c. using a tethering fusion protein to associate said exonic sequence and said target RNA.

### Claim 166 (depends on 165)

The method of claim 165, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule; and (b) a non-specific double-stranded RNA binding domain that stabilizes the RNA-RNA hybridization among the specific sequence and the target RNA.

### Claim 167 (depends on 166)

The method of claim 166, wherein the non-specific double-stranded RNA binding domain comprises sequences isolated or derived from a gene selected from the group consisting of: DGCR8, EIF2AK2, DICER1, ILF3, ADARB1, ADAR, STAU2, STAU1, PRKRA, EIF2AK2, RPS2, TRBP, CDKN2AIP, DHX9, NKRF, MRPL44, DUS2, TARBP2, DROSHA, IFIH14.

### Claim 168 (depends on 166)

The method of claim 166, wherein the RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule comprises sequences isolated or derived from a PUF or Pumby protein.

### Claim 169 (depends on 166)

The method of claim 166, wherein the RNA-binding domain that binds to a specific sequence encoded by the nucleic acid molecule comprises sequences isolated or derived from the gene SLBP.

### Claim 170 (depends on 165, 166, 167, 168, 169)

The method of any one of claims 165-169, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds a specific sequence encoded by said nucleic acid molecule; and (b) a domain that associates with the spliceosome.

### Claim 171 (depends on 165, 166, 167, 168, 169)

The method of any one of claims 165-169, wherein the tethering fusion protein comprises: (a) an RNA-binding domain that binds a specific sequence encoded by said nucleic acid molecule; and (b) a domain that associates with a transcriptional or spliceosomal complex.

### Claim 172 (depends on 165, 166, 167, 168, 169, 170, 171)

The method of any one of claims 165-171, wherein the tethering fusion protein is isolated or derived from human protein sequences.

### Claim 173 (depends on 165, 166, 167, 168, 169, 170, 171, 172)

The method of any one of claims 165-172, further comprising an engineered small nuclear RNA derived or isolated from the U1 snRNA gene that promotes trans-splicing among the target RNA and exonic sequence.

### Claim 174 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173)

The method of any one of claims 165-173, wherein the nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.

### Claim 175 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174)

The method of any one of claims 165-174, wherein the exonic sequence further comprises a sequence promotes accumulation of the exonic sequence in the cellular nucleus.

### Claim 176 (depends on 175)

The method of claim 175, wherein the sequence that promotes accumulation of the exonic sequence in the cellular nucleus is derived or isolated from a long noncoding RNA.

### Claim 177 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The method of any one of claims 165-176, wherein the nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 178 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The method of any one of claims 165-177, wherein the nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.

### Claim 179 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The method of any one of claims 165-178, wherein the nucleic acid molecule further encodes a gene expression-enhancing element.

### Claim 180 (depends on 179)

The method of claim 179, wherein the gene expression-enhancing element comprises a sequence derived or isolated from the group consisting of: Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE), triplex from MALAT1, the PRE of Hepatitis B virus (HPRE), and an iron response element.

### Claim 181 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The method of any one of claims 165-180, wherein the nucleic acid molecule comprises RNA, DNA, a DNA/RNA hybrid, a nucleic acid analog, a chemically-modified nucleic acid, or a chimera composed of two or more nucleic acids or nucleic acid analogs.

### Claim 182 (depends on 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The method of any one of claims 165-181, wherein the nucleic acid molecule further comprises a heterologous promoter.
